NCT06878859NARecruiting
Preliminary Efficacy Trial of a Digital Intervention for Depression and Cannabis Use
Massachusetts General Hospital
Start Date
2/23/2026
Completion Date
6/29/2029
Summary
The purpose of this study is to examine the feasibility, acceptability, and preliminary efficacy of a digital intervention for co-occurring cannabis use and depression. Participants will be randomized to complete Amplification of Positivity - Cannabis Use (AMP-C) or symptom tracking. The main outcomes will include changes in depressive symptoms and cannabis use, as well as usability ratings.
Eligibility Criteria
Age Range: 18 years to No maximum
Inclusion Criteria:
* Aged ≥ 18 years
* Resides in the United States
* Able to read and understand English and willing to provide informed consent/comply with the study protocol
* Moderate depressive symptom severity, as indicated by the Patient Health Questionnaire-9 (PHQ-9)
* Problematic cannabis use, as indicated by the Cannabis Use Disorder Identification Test - Revised (CUDIT-R)
* Current elevated anhedonia, as indicated by the PHQ-9
* Interest in receiving treatment for their cannabis use and depression
* Meet criteria for current MDD and CUD per the DSM-5
Exclusion Criteria:
* History of a psychotic disorder or bipolar disorder type I/II
* Active suicidal ideation or intent based on the Columbia-Suicide Severity Rating Scale
* Current psychotherapy engagement
* Changes in psychotropic medication within six weeks of the start of study
Interventions
BEHAVIORAL
Amplification of Positivity - Cannabis Use (AMP-C)
Conditions
Depression - Major Depressive DisorderCannabis Use DisorderMental Disorder
Locations
Massachusetts General Hospital
Boston, Massachusetts 02114
United States